Thanks for the link... You seem to be right on top of this stuff. Actually, I think I heard the presenter say that BSC has worldwide rights to their "inflatable" graft technology, and international distribution rights for Aorfix.
Regarding their drug delivery technology, it still sounded like they contemplated using polymer to elute drugs from the surface of a stent. That will make it difficult for them in the US. But then again, Lombard seems to have a relationship with BSC (who hold rights to the gatekeeper US patents in this area) and are now 10% owned by BSC. Appreciate your updates�